Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Perioperative Treatment in EGFR-Mutant Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Future Perspectives.

Thoracic cancer - 1 Feb 2025

Guo Xiaobei, Liu Xiaoyan, Guo Chao, Miao Qian, Cheng Xinghua, Hong Xuan, Li Hongru, Qiu Xiaoming, Xiang Yi, Zheng Di, Zhou Jian, Jiang Liyan, Xu Yan, Wang Mengzhao

Abstract excerpt

Adjuvant osimertinib administered over a 3-year period in patients diagnosed with stage IB-IIIA non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) mutations has not only shown improvement in event-free survival but also demonstrated a prolonged overall survival (OS), leading to its approval as a standard treatment in this context. Meanwhile, no targeted studies have been conducted on...

Read the complete abstract on PubMed

Topics

Humans
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
ErbB Receptors
Mutation
Perioperative Care

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Neoplasm Staging

Source

Open in PubMed Open full text

Identifiers

PMID: 39980151
DOI: 10.1111/1759-7714.70018
PMCID: PMC11842451

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 26 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Perioperative Treatment in EGFR-Mutant Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Future Perspectives.PMID 39980151Read ↗

Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges.Semantic proximity Read ↗

Perioperative Therapy in Oncogene-Driven Non-Small Cell Lung Cancer: Current Strategies and Unanswered Questions.Semantic proximity Read ↗

Perioperative targeted therapy for oncogene-driven NSCLC.Semantic proximity Read ↗

Perioperative immunotherapy for patients with EGFR mutant non-small cell lung cancer: Unexpected potential benefits.Semantic proximity Read ↗

Perioperative strategies for resectable EGFR-Mutant NSCLC: evidence hierarchy and clinical decision-making.Semantic proximity Read ↗

Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA).Semantic proximity Read ↗

Targeted Therapy in Early Stage Non-small Cell Lung Cancer.Semantic proximity Read ↗

Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

Role of EGFR-TKIs in Nonmetastatic Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Comprehensive Review.Semantic proximity Read ↗

Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review.Semantic proximity Read ↗

Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario.Semantic proximity Read ↗

Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.